Jared N. Cumming

An orally available non-nucleotide STING agonist with antitumor activity

Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 609 citations

Antitumor Activity, Immunology, Immunoediting +19

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 407 citations

Glucose Homeostasis, Bace1 Inhibitor Verubecestat, Enzyme 1 +20

Evidence for Fe(IV):O in the Molecular Mechanism of Action of the Trioxane Antimalarial Artemisinin

Gary H. Posner, Jared N. Cumming, Poonsakdi Ploypradith et al. · Journal of the American Chemical Society · 1995 · 173 citations

Bioorganic Chemistry, Antiparasitic Agent, Malaria +20

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

Jack D. Scott, Sarah W. Li, Andrew P. J. Brunskill et al. · Journal of Medicinal Chemistry · 2016 · 161 citations · Full text

Neurochemical Biomarkers, Peptide Science, Enzyme 1 +19

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

Jared N. Cumming, Elizabeth M. Smith, Lingyan Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 151 citations · Full text

Medicinal Chemistry, Drug Target, Active Bace1 Inhibitor +11